Fewer side effects found with newer breast cancer drug

04/17/2006 | Contra Costa Times (Walnut Creek, Calif.)

The National Cancer Institute said a government study shows raloxifene, currently used to treat osteoporosis, is as effective in older, high-risk women as tamoxifen in treating breast cancer, but with fewer side effects. Eli Lilly, which sells the drug as Evista, plans to seek FDA approval for the new indication.

View Full Article in:

Contra Costa Times (Walnut Creek, Calif.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC